Top 20 Oncology Companies Based on 2021 Oncology Segment Total Revenue

Shots:

Oncology focuses on the study, diagnosis, prevention, and treatment of cancer based on the treatment option and it’s divided into 3 major areas including medical oncology, radiation oncology, and surgical oncology
The advancements in cell and gene therapies have provided pharmaceutical companies with a unique set of ground-breaking tools for the development of more effective therapeutic options. As of 2020, Bristol-Myers Squibb (BMS) has once again secured the top position with total revenue of $29.73B, followed by Roche and Merck
Our team at PharmaShots has compiled a list of the top 20 oncology companies based on their 2021 oncology segment revenue

Oncology Segment Revenue: $0.037B

Founded Year: 1984

Market Cap: $8.90B

Total Employees: ~24,800

Headquarters: Hyderabad, India

Stock Exchange: NSE

Dr. Reddy’s Laboratories is an integrated pharma company that develops a wide range of generic formulations and proprietary products within the therapeutic areas including Oncology, Cardiovascular, Dermatology, Gastrointestinal, Diabetology, Nephrology & pain management. Dr. Reddy’s 2021 revenue increased by 12.1% vs 2020. On May’21, Dr. Reddy’s Lab. acquired the exclusive license to commercialize Pregene Biopharma’s PRG1801 in India and to also conduct the development and clinical trial of PRG1801 in India.

Oncology Segment Revenue: $0.63B

Founded Year: 2010

Market Cap: $16.88B

Total Employees: ~8,000

Headquarters: Beijing, China

Stock Exchange: NASDAQ

BeiGene is a global biotech company focused on the development and commercialization of innovative therapeutics in Oncology. Its products Tislelizumab and Brukinsa contributed the most to the company’s total revenue. BieGene’s 2021 revenue increased by 103.2% vs 2020. On Dec’21, BieGene entered into a collaboration and license agreement with Novartis for Ociperlimab (BGB-A1217) to strengthen its pipeline

Oncology Segment Revenue: $0.66B

Founded Year: 2000

Market Cap: $62.86B

Total Employees: ~92,000

Headquarters: Surrey, United Kingdom

Stock Exchange: LON

GSK is a global healthcare multinational company focused on the development and manufacturing of pharma products in areas including Oncology, Respiratory, and Immune Inflammation. GSK’s 2021 revenue increased by 29.4% vs 2020. On Apr’21 GSK’s Cabozantinib products Cabometyx and Cometriq were acquired by Royalty Pharma for an upfront payment of $342M along with additional payments of up to $50M.

Oncology Segment Revenue: $0.98B

Founded Year: 1987

Market Cap: $81.21B

Total Employees: ~14,400

Headquarters: California, United States

Stock Exchange: NASDAQ

Gilead Sciences is a biopharma company committed to the discovery, development, and commercialization of products for Antiretroviral Therapy, Oncology, Hematology, and Inflammatory & Respiratory diseases. The company’s Oncology segment includes Tecartus, Trodelvy, Yescarta, and Zydelig. Gilead’s 2021 revenue decreased by 7.5% vs 2020. On Oct’21, Gilead entered into a clinical trial collaboration with Merck to Evaluate Trodelvy + KEYTRUDA in patients with first-line metastatic triple-negative breast cancer.

Oncology Segment Revenue: $1.02B

Founded Year: 1973

Market Cap: $1.76B

Total Employees: ~95,400

Headquarters: Paris, France

Stock Exchange: NASDAQ

Sanofi is a French multinational biopharma company obligated to provide treatment options globally focused on therapeutic areas including Oncology, Cardiovascular, Neurology, Immunology, and Inflammation. Sanofi’s Oncology segment was boosted by the sales of its lead product, Jevtana. Sanofi’s 2021 revenue increased by 5.1% vs 2020. On Dec’21 Sanofi acquired Amunix’s Immuno-oncology pipeline that gave Bayer access to Amunix Pro-XTENTM, XPAT, and XPACTM technology.

Oncology Segment Revenue: $1.35B

Founded Year: 2005

Market Cap: $57.00B

Total Employees: ~15,000

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Daiichi Sankyo is a Japanese pharma company dedicated towards the development of novel therapies for therapeutic areas including Oncology and Rare Diseases. The total sale obtained by the company included the sales of Enhertu and Turalio. Daiichi Sankyo’s 2021 revenue was increased by 26.2% vs 2020. On Oct’21 Daiichi Sankyo entered into a clinical trial collaboration and supply agreement with Merck & Co. to evaluate the combination of Datopotamab Deruxtecan (Dato-DXd).

Oncology Segment Revenue: $1.43B

Founded Year: 1863

Market Cap: $50.92B

Total Employees: ~99,600

Headquarters: Leverkusen, Germany

Stock Exchange: ETR

Bayer is a global life science company that develops and commercializes a wide range of pharma products in Oncology, Cardiovascular, and kidney diseases. The products contributing to the company’s Oncology segment are Nexavar, Xofigo, and Stivarga. Bayer’s 2021 revenue inclined by 1.4% vs 2020. On Aug’21, Bayer completed the acquisition of Vividion.

Oncology Segment Revenue: $2.32B

Founded Year: 2002

Market Cap: $15.88B

Total Employees: ~2,100

Headquarters: Delaware, United States

Stock Exchange: NASDAQ

Incyte is an American biopharma company committed to the discovery, development, and commercialization of pharma products within a wide range of therapeutic areas including Hematology, Oncology, Inflammation, and Autoimmunity. The company’s net Oncology revenue was generated through its products Jakafi, Iclusig, Pemazyre, and Monjuvi. Incyte’s 2021 revenue inclined by 12.6% vs 2020. On Aug’21 Incyte and InnoCare entered into a collaboration and license agreement for the development and commercialization of Tafasitamab.

Oncology Segment Revenue: $3.86B

Founded Year: 1781

Market Cap: $42.14B

Total Employees: ~47,000

Headquarters: Tokyo, Japan

Stock Exchange: NYSE

Takeda is a Japanese multinational biopharma company that is dedicated towards its main target areas including Oncology, Metabolic Disorders, Gastroenterology, Neurology, and Immunology. The net sale of the company’s Oncology segment was based on the sales of Velcade, Leuplin, Ninlaro, Adcetris, Iclusig, and Alunbrig among others. Takeda’s 2021 revenue increased by 2.7% vs 2020. On Oct’21, Takeda’s TAK-228 & TAK-659 were acquired by Calithera to enhance its pipeline of clinical-stage targeted therapies.

Oncology Segment Revenue: $5.33B

Founded Year: 1923

Market Cap: $25B

Total Employees: ~14,500

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Astellas Pharma is a Japanese multinational pharma company committed to the development of novel therapies in therapeutic areas including Oncology, Nephrology, Urology, and Transplantation. Under the company’s Oncology segment, Xtandi had the most contribution to the total revenue. Astellas’ 2021 revenue improved by 15.9% vs 2020. On Jul’21 Astellas entered into a license agreement with ExCellThera for the in vivo use of the UM171 compound along with other molecules targeted towards the treatment of PSCs and PSC-derived cells.

Oncology Segment Revenue: $5.74B

Founded Year: 1876

Market Cap: $296.07B

Total Employees: ~35,000

Headquarters: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is a global pharma company that develops, manufactures, and commercializes therapies across therapeutic areas including Oncology, Immunology, Neurodegenerative Diseases, and Endocrinology. Amongst the company’s Oncology segment, Alimta contributed the highest amount to its net revenue. Eli Lilly’s 2021 revenue increased by 8.1% vs 2020. On Jul’21, Eli Lilly and Kumquat entered into a collaboration to jointly discover, develop, and commercialize potential novel small molecules that stimulate tumor-specific immune responses.

Oncology Segment Revenue: $7.23B

Founded Year: 2013

Market Cap: $245.25B

Total Employees: ~ 50,000

Headquarters: New York, United States

Stock Exchange: NYSE

AbbVie is a biopharma company that delivers novel therapeutic products across therapeutic areas including Oncology, Immunology, Dermatology, and Virology. The total sale obtained by the company included the sales of Imbruvica and Venclexta. Abbvie’s 2021 revenue inclined by 8.7% vs 2020. On Feb’21, AbbVie entered into a collaboration and license agreement with Caribou for the research and development of CAR-T cell therapies.

Oncology Segment Revenue: $8.28B

Founded Year: 1980

Market Cap: $130.95B

Total Employees: ~24,200

Headquarters: California, United States

Stock Exchange: NASDAQ

Amgen is an American biopharma company focused on the development of products across key therapeutic areas including Oncology, Neurology, Immunology, Nephrology, and Inflammation. The products under the company’s Oncology segment include Kyprolis, Blincyto, Vectibix, Kanjinti, Mvasi, Xgeva, Neulasta, Neupogen, Lumakras, and Sensipar. Amgen’s 2021 revenue decreased by 0.5% vs 2020. On Jul’21, Amgen acquired all the outstanding shares of Teneobio for $2.5M.

Oncology Segment Revenue: $12.33B

Founded Year: 1849

Market Cap: $2.49B

Total Employees: ~79,000

Headquarters: New York, United States

Stock Exchange: NYSE

Pfizer is an American multinational pharma and biotechnology company that works in a wide range of therapeutic areas including Oncology, Immunology, Cardiology, Endocrinology, and Neurology. The highest contributing product under its Oncology segment was Ibrance, followed by Xtandi and Inlyta. Pfizer’s 2021 revenue escalated by 13.5% vs 2020. On Apr’21, Pfizer entered into a worldwide licensing agreement with Celcuity to jointly develop and commercialize Gedatolisib for the treatment of breast cancer.

Oncology Segment Revenue: $13.05B

Founded Year: 1999

Market Cap: $187.13B

Total Employees: ~83,100

Headquarters: Cambridge, United Kingdom

Stock Exchange: LON

AstraZeneca is a multinational pharma and biotech company that delivers products in therapeutic areas including Oncology, Cardiology, Gastrointestinal infections, and Inflammation. Tagrisso was the key player in its Oncology segment generating the total revenue. AstraZeneca’s 2021 revenue improved by 20.3% vs 2020. On Nov’21, AstraZeneca entered into a $3.5M collaborative research project with BioMark and Pfizer to enhance the efficiency of current lung cancer screening programs.

Oncology Segment Revenue: $14.54B

Founded Year: 1886

Market Cap: $431.37B

Total Employees: ~141,700

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Johnson & Johnson (J&J) is an American multinational pharma company that provides treatment options for multiple therapeutic areas including Cardiovascular, Oncology, Immunology, and Endocrinology. Darzalex, Erleada, Imbruvica, and Zytiga are the products under its Oncology segment with Darzalex adding a great value ($6.02B) to the total revenue. J&J’s 2021 revenue increased by 17.6% vs 2020. In Jan’21 J&J entered into a collaboration with Revitope Oncology to jointly evaluate Revitope’s T cell engager technology platform.

Oncology Segment Revenue: $15.48B

Founded Year: 1996

Market Cap: $198.75B

Total Employees: ~108,000

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Novartis is a Swiss multinational pharma company that provides treatment options for diseases including Oncology, Hepatology, Immunology, Dermatology, Musculoskeletal Diseases, Neuroscience, and Ophthalmology. The company’s Oncology segment includes products for the treatment of Hematology and Solid Tumors. Novartis’ 2021 revenue inclined by 5.2% vs 2020. On Feb’21, Novartis and BeiGene collaborated to jointly develop and commercialize Tislelizumab in North America, Europe, and Japan.

Oncology Segment Revenue: $19B

Founded Year: 1891

Market Cap: $220.07B

Total Employees: ~68,000

Headquarters: New Jersey, United States

Stock Exchange: NYSE

Merck is an American multinational pharma company involved in the development, manufacturing, and marketing of pharma products including Oncology, Infectious Diseases, Respiratory, and Immunology. Keytruda ($17.19B) was the key player in generating the total sales of the company’s net Oncology sales. Merck’s 2021 revenue was boosted by 20.1% vs 2020. In Aug’21 Merck entered into a clinical collaboration with Hookipa for the evaluation of HB-200 in patients with advanced head and neck cancer.

Oncology Segment Revenue: $22.45B

Founded Year: 1896

Market Cap: $281.66B

Total Employees: ~100,920

Headquarters: Basel, Switzerland

Stock Exchange: SWX

Roche is a Swiss multinational company dedicated towards providing therapeutic options across areas including Oncology, Immunology, Ophthalmology, Cardiovascular, and Respiratory. Amongst the Oncology segment of Roche, Perjeta had the highest contribution to the total revenue. Roche’s 2021 revenue declined by 14.8% vs 2020. On Aug’21, Roche entered into a cooperation agreement with Shanghai KeChow Pharma to jointly improve the commercialization of Zelboraf in China

Oncology Segment Revenue: $29.73B

Founded Year: 1887

Market Cap: $123.31B

Total Employees: ~32,200

Headquarters: New York, United States

Stock Exchange: NYSE

Bristol-Myers Squibb (BMS) is a pharma company that provides therapies for Oncology, Cardiovascular & Immunological diseases. Revlimid ($12.82B) and Eliquis ($10.76B) were among the company’s highest contributing Oncology products. BMS’ 2021 revenue was increased by 7.4% vs 2020. On Dec’21, BMS entered into a global exclusive license agreement with Immatics for the development of Immatics’ TCR Bispecific candidate IMA401.

Sources: